ImmuPharma (LON:IMM) Trading Up 29% - Time to Buy?

Key Points

• ImmuPharma's stock price increased by 29%, reaching a high of GBX 10.50 during trading, significantly higher than its previous close of GBX 8.06.
• The company has a market capitalization of £51.97 million and has reported a negative P/E ratio of -1,168.54 along with a net margin of 3,519.56%.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, Lupuzor™, aimed at treating autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price shot up 29% during trading on Tuesday . The company traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.40 ($0.14). 29,117,717 shares were traded during trading, an increase of 290% from the average session volume of 7,457,263 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Stock Up 29.0%

The company has a market cap of £51.97 million, a P/E ratio of -1,168.54 and a beta of 1.53. The firm's 50 day moving average is GBX 2.38 and its two-hundred day moving average is GBX 2.70.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.